Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
03:14pm, Friday, 19'th Dec 2025
Officials pledge ‘massive savings' as companies agree to offer drugs at prices paid in other wealthy countries
Nine of the largest pharma companies ink deals with Trump to lower drug prices
02:34pm, Friday, 19'th Dec 2025
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug
Here's Why GSK (GSK) is a Strong Growth Stock
10:46am, Friday, 19'th Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
10:36am, Friday, 19'th Dec 2025
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare
GSK: 2026 Looks Good
04:25pm, Thursday, 18'th Dec 2025
GSK has surged ~46% YTD, far outpacing both the healthcare sector and S&P 500, which is notable considering the spectre of high US tariffs hanging over it. The recent US-UK pharmaceuticals deal, the c
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
11:30am, Wednesday, 17'th Dec 2025
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
First Look: WBD rejects PSKY bid; Ford pivots; Tesla faces DMV order
07:37am, Wednesday, 17'th Dec 2025
Stock News WBD backs Netflix, rejects PSKY bid: Warner Bros. Discovery (WBD) urged shareholders to reject Paramount Skydance's (PSKY) $30-per-share hostile tend
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
09:55pm, Tuesday, 16'th Dec 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of sev
US FDA approves GSK's twice-yearly asthma drug
06:10pm, Tuesday, 16'th Dec 2025
The U.S. Food and Drug Administration has approved GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dos
UK approves GSK's twice-yearly asthma drug
12:02pm, Monday, 15'th Dec 2025
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adult
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
11:31am, Monday, 15'th Dec 2025
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
05:35pm, Friday, 12'th Dec 2025
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending
GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)
04:42pm, Friday, 12'th Dec 2025
GSK has been impressing me with strong revenue and EPS numbers for the eighth quarter in a row. Also, on December 12, depemokimab, GSK's anti-IL-5 antibody with 6-month dosing, received a positive EMA
GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe
01:53pm, Friday, 12'th Dec 2025
Analysts are increasingly focusing on GSK (GSK) after Europe's drug regulator delivered what could be a pivotal endorsement for depemokimab, a treatment positio
